<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02995096</url>
  </required_header>
  <id_info>
    <org_study_id>There is no unique protocol ID</org_study_id>
    <nct_id>NCT02995096</nct_id>
  </id_info>
  <brief_title>Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma</brief_title>
  <official_title>The Effect of Tumor Characteristics, Pre-transplant Treatments and Immunosuppression on Survival After Liver Transplantation for Hepatocellular Carcinoma - a European Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrence after liver transplantation for hepatocellular carcinoma (HCC) represents an
      important cause of mortality for this surgical population. In addition to tumor
      characteristics, It has been suggested that pre-treatment and sirolimus-based
      immunosuppression may affect recurrence and survival. With data from the European Liver
      Transplant Registry (ELTR) database, the aim of this study is to investigate the impact of
      tumor characteristics, pre-transplant treatment and immunosuppression regimens on survival
      after liver transplantation for HCC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 10 year survival</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatocellular carcinoma specific survival</measure>
    <time_frame>5 year and 10 year survival</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">23124</enrollment>
  <condition>Liver Transplantation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pre-treatment</intervention_name>
    <description>Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus based immunosuppression</intervention_name>
    <description>Immunosuppression regimens containing Sirolimus</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving liver transplantation for hepatocellular carcinoma in European centers
        reporting to the ELTR database.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatocellular carcinoma within transplantation criteria

        Exclusion Criteria:

          -  Disseminated disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Christian Pommergaard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Surgery and Transplantion, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>December 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2016</study_first_posted>
  <last_update_submitted>March 31, 2019</last_update_submitted>
  <last_update_submitted_qc>March 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Hans-Christian Pommergaard, MD, PhD</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The database material is available for researcher applying for data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

